Identifying low data protein targets: Cyclica’s MatchMaker™ platform
A key part of Cyclica’s competitive advantage is our scientific differentiation. In this video, we hear from Mike Palovich, PhD, Chief Scientific Officer and Head of Drug Discovery at Cyclica.
Mike discusses how our proprietary platform, MatchMaker™, has a high success rate at identifying novel small molecules for low data protein targets, also known as the 'dark proteome'. These targets have exciting potential to bring novel medicines to patients. Learn more about our science and platform here: https://cyclicarx.com/science/.